COL17A1 and breast neoplasm: This revealed that the COL17A1 promoter is indeed hypermethylated in breast tumors (n = 735 tumors, n = 92 normal samples; p < 0.0001, Mann-Whitney U test; Fig. 4b, c) and this hypermethylation is independent of COL17A1 allelic copy number variations (p < 0.0001; Fig. 4c).